Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2002
12/27/2002WO2002102344A2 No-synthase inhibitor and use thereof
12/27/2002WO2002102315A2 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
12/27/2002WO2002102314A2 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102313A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102310A2 Proteins associated with cell growth, differentiation, and death
12/27/2002WO2002102297A2 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
12/27/2002WO2002088330A3 Neural progenitor cells
12/27/2002WO2002087626A9 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
12/27/2002WO2002076946A3 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
12/27/2002WO2002072144A9 Remedies for nerve damages
12/27/2002WO2002070473A3 Carboxamide derivatives as therapeutic agents
12/27/2002WO2002060922A3 Epoxyvibsanin b
12/27/2002WO2002058666A3 Process for preparing non-hygroscopic sodium valproate composition
12/27/2002WO2002056907A3 Molecular antigen array presenting amyloid beta
12/27/2002WO2002055720A9 Materials and methods relating to protein aggregation in neurodegenerative disease
12/27/2002WO2002055099A3 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
12/27/2002WO2002045695A3 Hydrostatic delivery system for controlled delivery of agent
12/27/2002WO2002029065A3 Retroviral vectors containing internal ribosomal entry sites
12/27/2002WO2002018445A8 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
12/27/2002WO2002011712A3 Combination of huperzine and nicotinic compounds as a neuroprotective agent
12/27/2002WO2002005851A8 Enhancement of the action of central and peripheral nervous system agents
12/27/2002WO2001085937A3 Regulator of g protein signalling (rgs8)
12/27/2002WO2001083715A8 Derivation of midbrain dopaminergic neurons from embryonic stem cells
12/27/2002WO2001074903A9 Cd20/ige-receptor like molecules and uses thereof
12/27/2002WO2001052855A8 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
12/27/2002WO2001034631A3 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
12/27/2002CA2782868A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782865A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782862A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782857A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782791A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782761A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782628A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782623A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782615A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782521A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
12/27/2002CA2782519A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
12/27/2002CA2782517A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
12/27/2002CA2782515A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782494A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2451475A1 Agent for protection of retinal neurons
12/27/2002CA2451057A1 Novel isoxazolopyridone derivatives and use thereof
12/27/2002CA2450936A1 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450809A1 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002CA2450724A1 Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450678A1 Novel polypeptide and use thereof
12/27/2002CA2450659A1 Tryptase inhibitors
12/27/2002CA2450245A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity
12/27/2002CA2450074A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
12/27/2002CA2450067A1 Proteins associated with cell growth, differentiation, and death
12/27/2002CA2449977A1 Human growth hormone antagonists
12/27/2002CA2449916A1 Imidazole derivatives for modulating sodium channels
12/27/2002CA2447808A1 A process for preparing paroxetine hci which limits formation of pink colored compounds
12/27/2002CA2445261A1 Human tachykinin-related splice variants and compositions thereof
12/27/2002CA2444876A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
12/27/2002CA2444356A1 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
12/27/2002CA2430627A1 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
12/26/2002US20020198387 Reacting N-alkylpiperidine with a haloformic acid ester to prepare an alkoxycarbonylpiperidine, hydrolyzing
12/26/2002US20020198377 For improving perception, concentration power, learning power and/ or memory power
12/26/2002US20020198367 DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof
12/26/2002US20020198261 Liquid pharmaceutical compositions
12/26/2002US20020198257 Halogenated 2-phenyl-1,2-ethanediol monocarbamate derivatives
12/26/2002US20020198253 Melatonin derivatives and medicine containing same
12/26/2002US20020198251 Substituted 2-dialkylaminoalkylbiphenyl derivatives
12/26/2002US20020198248 Therapeutic methods and compositions involving isoflavones
12/26/2002US20020198245 Heterocyclic aromatic oxazole compounds and use thereof
12/26/2002US20020198244 Heterocyclic aromatic oxazole compounds and use thereof
12/26/2002US20020198237 2,5-substituted imidazole compounds useful as histamine H3 receptor mediators
12/26/2002US20020198236 Small organic molecule regulators of cell proliferation
12/26/2002US20020198234 Identifying a patient suffering from fatigue arising from oncological condition, and administering to the patient a therapeutically effective amount of D-threo-methylphenidate free of 1-threo isomer
12/26/2002US20020198232 4-substituted quinoline derivatives
12/26/2002US20020198231 Compositions and methods for the treatment of Parkinson's disease
12/26/2002US20020198226 Administration of an opioid analgesic agent(such as morphine, codeine, methadone and fentanyl) and a compound that binds to the SS1 or SS2 subunit of a sodium channel , such as tetrodotoxin and saxitonxin and derivatives
12/26/2002US20020198219 2-pyridinamine compositions and related methods
12/26/2002US20020198218 Synthesis and methods of use of tetrahydroindolone analogues and derivatives
12/26/2002US20020198217 Such as benzyl-(-7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta(a)naphthalen-8-ylmethyl) -amine; for treatment of drug dependence/addiction, bipolar disorder, Parkinson's disease, levodopa induced psychoses or dyskinesias
12/26/2002US20020198214 Such as (3-(4-(4-fluoro-benzyl)-piperidine-1-carbonyl)-4-methoxy-phenyl)-oxo-acetic acid methyl ester for proinflammation response in multiple sclerosis, inflammatory bowel disease, osteoarthritis, and other arthritic conditions
12/26/2002US20020198213 Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
12/26/2002US20020198211 cDNA for human methylenetetrahydrofolate reductase and uses thereof
12/26/2002US20020198198 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
12/26/2002US20020198197 Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders
12/26/2002US20020198190 Tetracyclic 1,2,3,4,5,6- hexahydroazepino-(4,5-b)indole derivatives having a ring connecting position 6 (N-6) and position 7 (C-7); treating or preventing a disease or disorder of the central nervous system in a mammal
12/26/2002US20020198179 An estrogen or prodrug micture for reducing or eliminating the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer, inhibiting the development of osteoporosis
12/26/2002US20020198177 Coenzyme Q and EPA
12/26/2002US20020198170 Formulations of adenosine a1 agonists
12/26/2002US20020198152 Administering to an obese patient or one at risk of becoming obese a therapeutic compound that attenuates the binding of agouti-related protein to melanocortin receptors, free of binding of alpha-melanocyte stimulating hormone to receptor
12/26/2002US20020198143 B7-like polynucleotides, polypeptides, and antibodies
12/26/2002US20020197737 Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
12/26/2002US20020197692 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
12/26/2002US20020197675 Glial nerovus system modulator for use in the treatment of nervous system disorders and spine damage
12/26/2002US20020197381 Caffeine complexes with enhanced taste, process for their preparation and their use
12/26/2002US20020197318 Compositions
12/26/2002US20020197279 Methods for treating tension headache
12/26/2002US20020197266 Immunotherapy using interleukin 13 receptor subunit alpha 2
12/26/2002US20020197238 Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells
12/26/2002US20020197235 Method for short-term and long-term drug dosimetry
12/26/2002US20020197233 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
12/26/2002CA2391568A1 Collapsin response mediator protein-1
12/25/2002CN1387571A Mammalian cytokines, related reagents and methods
1 ... 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 ... 1833